Device Trial Radar · NCT00839384
AdvisaTM IPG Clinical Evaluation Study
Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Feb 2009
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
- Sponsor type
- Industry
- Collaborators
- Medtronic
- First posted
- Feb 9, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Advisa IPG clinical study is to evaluate the overall system safety and clinical performance of the Advisa DR Implantable Pulse Generator (IPG).
Conditions
- Bradycardia
- Atrial Tachyarrhythmia
Interventions
Advisa IPGDevice
Implantable Pulse Generator will be implanted
Primary outcomes
What the sponsor says the trial is designed to measure.
- USADE at 1 month post implantTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IKEM
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.